Stock Analysis on Net
Stock Analysis on Net

Medtronic PLC (NYSE:MDT)

$24.99

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

Try for free

Medtronic PLC pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Medtronic PLC, consolidated cash flow statement

US$ in millions

Microsoft Excel
12 months ended: Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020 Apr 26, 2019
Net income
Depreciation and amortization
Provision for credit losses
Deferred income taxes
Stock-based compensation
Loss on debt extinguishment
Asset impairments and related inventory write-downs
Other, net
Accounts receivable, net
Inventories, net
Accounts payable and accrued liabilities
Other operating assets and liabilities
Change in operating assets and liabilities, net of acquisitions and divestitures
Adjustments to reconcile net income to net cash provided by operating activities
Net cash provided by operating activities
Acquisitions, net of cash acquired
Additions to property, plant, and equipment
Purchases of investments
Sales and maturities of investments
Other investing activities, net
Net cash used in investing activities
Change in current debt obligations, net
Proceeds from short-term borrowings, maturities greater than 90 days
Repayments from short-term borrowings, maturities greater than 90 days
Issuance of long-term debt
Payments on long-term debt
Dividends to shareholders
Issuance of ordinary shares
Repurchase of ordinary shares
Other financing activities
Net cash used in financing activities
Effect of exchange rate changes on cash and cash equivalents
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

Based on: 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Medtronic PLC net cash provided by operating activities decreased from 2022 to 2023 but then increased from 2023 to 2024 not reaching 2022 level.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Medtronic PLC net cash used in investing activities decreased from 2022 to 2023 but then increased from 2023 to 2024 not reaching 2022 level.
Net cash used in financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Medtronic PLC net cash used in financing activities increased from 2022 to 2023 and from 2023 to 2024.